Levicept develops biological agent for the treatment of chronic pain.
Levicept has raised $47.8M in total funding. The most recent round was Series B. The last funding was announced in September 2021.
Levicept's investors include Index Ventures, Pfizer Venture Investments, Innovate UK, Gilde Healthcare, Medicxi.
Levicept is headquartered in Sandwich, United Kingdom.
Levicept develops biological agent for the treatment of chronic pain.
Levicept is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Levicept — Funding & Investors." VCBacked, September 21, 2021, https://www.vcbacked.co/company/levicept. Accessed September 29, 2026.
VCBacked. (2021). Levicept — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/levicept
{{cite web |title=Levicept — Funding & Investors |url=https://www.vcbacked.co/company/levicept |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated